Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the
bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is
a HIV medication that works by blocking the entry of HIV in cells including
monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the
addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high
levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected
monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance
spectroscopy (MRS, a form of MRI study).